Objective
Our proposal is to develop new treatment strategies for Invasive Aspergillosis (IA) which has become the major infectious complication of treating haematological malignancies with intensive chemotherapy or haematopoietic stem cell transplantation (HSCT). It meets the criteria of the call by addressing a disease with a significant economic cost due to "resistance" to treatment with available agents and high associated mortality. Ineffective host immune responses facilitate fungal invasion of the pulmonary system and other vital organs leading to death.
In order to redress this immunological imbalance we propose to develop new immunotherapeutic strategies which will augment current antifungal treatments and reduce morbidity and mortality. We plan to study high risk patients undergoing allogenetic HSCT to prove our hypothesis that immunotherapy is efficacious. Facilitated by recent publication of the Aspergillus fumigatus (the principal pathogen of the genus) genome sequence we will exploit new knowledge and techniques in genomics and proteomics. We will identify the immuno-logically important fungal targets to aid design of immunotherapies based on vaccines using fungus-primed innate immune cells, monoclonal antibodies or adoptive transfer of specific T lymphocyte clones. We will also generate new nucleic acid based diagnostic tests to inform when and how immunotherapy can be optimally applied.
The findings generated will be of great relevance to treatment of haematological malignancies throughout the EU by significantly reducing HSCT related mortality, by allowing more intensive cancer treatment regimens to be used leading to higher remission rates, and will also be applicable to other patient populations at risk of IA. The outcomes will have strong commercial applications which will be delivered by three leading European SMEs within the consortium.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences medical biotechnology cells technologies stem cells
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs vaccines
- medical and health sciences clinical medicine oncology
- medical and health sciences basic medicine immunology immunotherapy
- medical and health sciences clinical medicine transplantation
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP6-2005-LIFESCIHEALTH-7
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
WUERZBURG
Germany
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.